Inflammation-focused Rezera sets terms for IPO
Rezera, formerly known as NodThera, has announced the terms of its planned IPO, hoping to raise upwards of $200m for its NLRP3 inhibitor pipeline.
Newsletters and Deep Dive digital magazine
Rezera, formerly known as NodThera, has announced the terms of its planned IPO, hoping to raise upwards of $200m for its NLRP3 inhibitor pipeline.
Two more Ebola vaccines are set to be added to a trial in the Democratic Republic of the Congo (DRC), currently battling its largest-ever outbreak.
Following ASN Kidney Week 2026, pharmaphorum spoke with Hansa Biopharma's Maria Törnsén and Tes Pharma's Andrea Pellacani about the conference.
UK start-up Potential Sciences emerged from stealth today with a sizeable seed funding round and an ambition to transform drug discovery with AI.
Two up-and-coming UK biotechs – T-Therapeutics and Alethio Therapeutics – have raised $133m and $90m, respectively, in impressive financing rounds.
Editor's Picks
Newsletters and Deep Dive
digital magazine